These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 31529299

  • 1. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G.
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [Abstract] [Full Text] [Related]

  • 2. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S.
    Ann Oncol; 2019 Feb 01; 30(2):236-242. PubMed ID: 30590484
    [Abstract] [Full Text] [Related]

  • 3. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Noda S, Takashima T, Onoda N, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    BMC Cancer; 2017 Dec 28; 17(1):888. PubMed ID: 29282021
    [Abstract] [Full Text] [Related]

  • 4. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
    Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV.
    Clin Cancer Res; 2023 Sep 01; 29(17):3429-3437. PubMed ID: 37417941
    [Abstract] [Full Text] [Related]

  • 5. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N, Qiu J, Wu J, Zeng H, Su F, Qiu K, Wu J, Yao H.
    Chemotherapy; 2017 Sep 01; 62(4):246-255. PubMed ID: 28472798
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X, Tan Q, Li H, Yang X.
    J Surg Oncol; 2021 Jan 01; 123(1):89-95. PubMed ID: 33047336
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G, Wang Z, Qu X, Zhang Z.
    BMC Cancer; 2020 Mar 04; 20(1):179. PubMed ID: 32131780
    [Abstract] [Full Text] [Related]

  • 11. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K, Ohi Y, Tanimoto A.
    Breast Cancer Res Treat; 2019 Nov 04; 178(2):283-294. PubMed ID: 31402409
    [Abstract] [Full Text] [Related]

  • 12. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, Cumerlato E, Massa D, Lo Mele M, Orvieto E, Guarneri V, Conte P.
    Eur J Cancer; 2020 Sep 04; 136():7-15. PubMed ID: 32622323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N.
    Eur J Cancer; 2019 Sep 04; 118():41-48. PubMed ID: 31302586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    Anticancer Res; 2018 Apr 04; 38(4):2311-2321. PubMed ID: 29599354
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S, Chung YR, Seo AN, Kim M, Woo JW, Park SY.
    PLoS One; 2020 Apr 04; 15(5):e0233037. PubMed ID: 32401825
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F.
    PLoS One; 2020 Apr 04; 15(6):e0234191. PubMed ID: 32579551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.